News

News and Press Releases
Our Research Approach Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF

Prime Medicine’s prime editing technology has the potential to bring genetic therapies to all people with cystic fibrosis, ultimately paving the way to a cure.

| 4 min read
Our Research Approach CF Foundation Invests Up to $9 Million in Arcturus Therapeutics to Develop a Messenger RNA Therapy

The Cystic Fibrosis Foundation is providing additional funding to Arcturus Therapeutics to develop an inhaled messenger RNA therapy for CF that provides lung cells with the correct instructions to make functional cystic fibrosis transmembrane conductance regulator protein. The funding brings our total commitment to Arcturus to approximately $25 million.

| 3 min read
Our Research Approach CF Foundation Invests Up to $2 Million in Nosis Bio for Potential Gene Therapy Delivery Technology

Nosis Bio, an inaugural winner of the Foundation’s Golden Ticket Competition, receives funding to further explore design of novel ligands, which are specialized molecules that could help more precise targeting of relevant cells in the lung. 

| 3 min read
Our Research Approach CF Foundation Invests Up to $15M in ReCode Therapeutics for Development of mRNA Therapy

Funding will support preclinical research and early-stage clinical trials

| 3 min read
About the CF Foundation | Our Research Approach Cystic Fibrosis Foundation Invests $6M in Carbon Biosciences to Advance New Gene Therapy Approach for Cystic Fibrosis

Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab

| 4 min read
About the CF Foundation | Our Research Approach Cystic Fibrosis Foundation Invests $5 Million in Sionna Therapeutics to Develop New CFTR Modulator Therapy

New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease

| 3 min read
Clinical Trials | Our Research Approach CF Foundation Funds Expansion of Clinical Trial Program for Potential Nonsense Mutations Therapy

The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.

| 4 min read
About the CF Foundation | Our Research Approach Cystic Fibrosis Foundation Announces Investment in SalioGen Therapeutics to Fund Genetic Therapies Research

Investment will support discovery research of a novel Gene CodingTM approach that could benefit all people with CF regardless of their mutation
 

| 5 min read
About the CF Foundation | Clinical Trials | Our Research Approach CF Foundation Awards Up to $5 Million to BiomX for Potential Phage Therapy

Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance

| 4 min read
Research | About the CF Foundation | Our Research Approach CF Foundation Awards Contract to Life Edit Therapeutics to Explore Gene Editing Technology in CF

Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.

| 3 min read